Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON

Atle Fund Management AB increased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 85.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,690 shares of the company’s stock after purchasing an additional 21,038 shares during the quarter. Disc Medicine makes up about 1.2% of Atle Fund Management AB’s holdings, making the stock its 29th biggest position. Atle Fund Management AB owned approximately 0.13% of Disc Medicine worth $3,019,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in IRON. Arizona State Retirement System lifted its position in shares of Disc Medicine by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock worth $440,000 after buying an additional 120 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after acquiring an additional 181 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after acquiring an additional 206 shares during the last quarter. HighVista Strategies LLC lifted its holdings in Disc Medicine by 4.3% during the second quarter. HighVista Strategies LLC now owns 6,733 shares of the company’s stock worth $357,000 after acquiring an additional 275 shares during the period. Finally, Avanza Fonder AB increased its position in shares of Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after purchasing an additional 585 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $77.32 on Friday. The firm has a market capitalization of $2.92 billion, a PE ratio of -14.45 and a beta of 0.87. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average price of $83.23 and a two-hundred day moving average price of $74.08. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Activity at Disc Medicine

In other news, CEO John D. Quisel sold 40,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $93.05, for a total value of $3,722,000.00. Following the sale, the chief executive officer directly owned 171,828 shares of the company’s stock, valued at approximately $15,988,595.40. This represents a 18.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin Bitterman sold 754 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $91.47, for a total transaction of $68,968.38. Following the completion of the transaction, the director owned 14,013 shares of the company’s stock, valued at $1,281,769.11. This trade represents a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 275,470 shares of company stock worth $24,966,170 in the last 90 days. 3.64% of the stock is owned by company insiders.

Analysts Set New Price Targets

IRON has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, January 21st. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a research report on Friday, October 17th. UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. TD Cowen reissued a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of “Moderate Buy” and an average price target of $119.45.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.